KEGG   DRUG: EvolocumabHelp
Entry
D10557                      Drug                                   

Name
Evolocumab (USAN/INN);
Evolocumab (genetical recombination) (JAN);
Repatha (TN)
Product
Formula
C6242H9648N1668O1996S56
Exact mass
141700.9089
Mol weight
141789.0125
Sequence
(Heavy chain)
EVQLVQSGAE VKKPGASVKV SCKASGYTLT SYGISWVRQA PGQGLEWMGW VSFYNGNTNY
AQKLQGRGTM TTDPSTSTAY MELRSLRSDD TAVYYCARGY GMDVWGQGTT VTVSSASTKG
PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
SSVVTVPSSN FGTQTYTCNV DHKPSNTKVD KTVERKCCVE CPPCPAPPVA GPSVFLFPPK
PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTFRVVSVL
TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI SKTKGQPREP QVYTLPPSRE EMTKNQVSLT
CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR WQQGNVFSCS
VMHEALHNHY TQKSLSLSPG K
(Light chain)
ESALTQPASV SGSPGQSITI SCTGTSSDVG GYNSVSWYQQ HPGKAPKLMI YEVSNRPSGV
SNRFSGSKSG NTASLTISGL QAEDEADYYC NSYTSTSMVF GGGTKLTVLG QPKAAPSVTL
FPPSSEELQA NKATLVCLIS DFYPGAVTVA WKADSSPVKA GVETTTPSKQ SNNKYAASSY
LSLTPEQWKS HRSYSCQVTH EGSTVEKTVA PTECS
(dimer; disulfide bridge: H22-H96, H129-L124, H142-H198, H217-H'217, H218-H'218, H221-H'221, H224-H'224, H255-H315, H361-H419, H'22-H'96, H'129-L'214, H'142-H'198, H'255-H'315, H'361-H'419, L22-L90, L137-L196, L'22-L'90, L'137-L'196)
  Type
Peptide
Class
Cardiovascular agent
 DG01946  Hypolipidemic agent
Remark
Therapeutic category: 
ATC code: 
Efficacy
Antihyperlipidemic, Anti-PCSK9 antibody
  Disease
Primary hyperlipidemia [DS:H01635]
Homozygous familial hypercholesterolemia [DS:H00155 H01383]
Comment
Monoclonal antibody
Target
PCSK9 [HSA:255738] [KO:K13050]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 C CARDIOVASCULAR SYSTEM
  C10 LIPID MODIFYING AGENTS
   C10A LIPID MODIFYING AGENTS, PLAIN
    C10AX Other lipid modifying agents
     C10AX13 Evolocumab
      D10557  Evolocumab (USAN/INN)
USP drug classification [BR:br08302]
 Cardiovascular Agents
  Dyslipidemics, Other
   Evolocumab
    D10557  Evolocumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  21  Cardiovascular agents
   218  Hyperlipidemia agents
    2189  Others
     D10557  Evolocumab (USAN/INN); Evolocumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases
   proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Evolocumab
     D10557  Evolocumab (USAN/INN)
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D10557
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10557
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10557
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10557
Orphan drugs in the USA [br08355.html]
 Orphan drugs in the USA
  D10557
Pharmacogenomic biomarkers in FDA drug labels [br08341.html]
 Polymorphisms and germline mutations
  D10557
BRITE hierarchy
Other DBs
CAS: 
1256937-27-5 1420806-15-0
PubChem: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system